Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta has entered into an exclusive worldwide licensing agreement with Daiichi Sankyo Company, for the development and commercialization of an oncology product, tesetaxel.
Subscribe to our email newsletter
Under terms of the agreement, Daiichi Sankyo will receive upfront payments, payments pursuant to the achievement of certain milestones, and royalties on product sales.
Raymond Warrell, Jr., chairman and CEO of Genta, said: “During our extended analysis of this compound, FDA provided clear and specific guidance regarding the tasks that would be required to lift the clinical hold. We believe these tasks are straightforward and we look forward to resuming key clinical trials.”